Disproportionality Analysis of Gastrointestinal Adverse Events Associated With Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report database

Gastrointestinal adverse events associated with T-DXd can arise early or later in treatment and may lead to serious or fatal outcomes. These findings underscore the importance of continuous post-marketing surveillance and proactive clinical management to detect and mitigate these potentially severe AEs.